| 000 | 01764 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515075957.0 | ||
| 264 | 0 | _c20071024 | |
| 008 | 200710s 0 0 eng d | ||
| 022 | _a0027-8424 | ||
| 024 | 7 |
_a10.1073/pnas.0702654104 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHantschel, Oliver | |
| 245 | 0 | 0 |
_aThe Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. _h[electronic resource] |
| 260 |
_bProceedings of the National Academy of Sciences of the United States of America _cAug 2007 |
||
| 300 |
_a13283-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBasophils _xdrug effects |
| 650 | 0 | 4 | _aDasatinib |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aFusion Proteins, bcr-abl |
| 650 | 0 | 4 |
_aHistamine Release _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aK562 Cells |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrimidines _xpharmacology |
| 650 | 0 | 4 |
_aThiazoles _xpharmacology |
| 650 | 0 | 4 | _aU937 Cells |
| 700 | 1 | _aRix, Uwe | |
| 700 | 1 | _aSchmidt, Uwe | |
| 700 | 1 | _aBürckstümmer, Tilmann | |
| 700 | 1 | _aKneidinger, Michael | |
| 700 | 1 | _aSchütze, Gregor | |
| 700 | 1 | _aColinge, Jacques | |
| 700 | 1 | _aBennett, Keiryn L | |
| 700 | 1 | _aEllmeier, Wilfried | |
| 700 | 1 | _aValent, Peter | |
| 700 | 1 | _aSuperti-Furga, Giulio | |
| 773 | 0 |
_tProceedings of the National Academy of Sciences of the United States of America _gvol. 104 _gno. 33 _gp. 13283-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1073/pnas.0702654104 _zAvailable from publisher's website |
| 999 |
_c17216172 _d17216172 |
||